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Abstract: Cardiovascular disease (CVD) represents the leading cause of mortality worldwide. 
Lifestyle modifications, along with low-density lipoprotein cholesterol (LDL-C) reduction, 
remain the highest priorities in CVD risk management. Among lipid-lowering agents, statins 
are most effective in LDL-C reduction and have demonstrated incremental benefits in CVD risk 
reduction. However, in light of the residual CVD risk, even after LDL-C targets are achieved, 
there is an unmet clinical need for additional measures. Fibrates are well known for their 
  beneficial effects in triglycerides, high-density lipoprotein cholesterol (HDL-C), and LDL-C 
subspecies modulation. Fenofibrate is the most commonly used fibric acid derivative, exerts 
  beneficial effects in several lipid and nonlipid parameters, and is considered the most suitable 
fibrate to combine with a statin. However, in clinical practice this combination raises concerns 
about safety. ABT-335 (fenofibric acid, Trilipix®) is the newest formulation designed to overcome 
the drawbacks of older fibrates, particularly in terms of pharmacokinetic properties. It has been 
extensively evaluated both as monotherapy and in combination with atorvastatin, rosuvastatin, 
and simvastatin in a large number of patients with mixed dyslipidemia for up to 2 years and 
appears to be a safe and effective option in the management of dyslipidemia.
Keywords: atherogenic dyslipidemia, cardiovascular disease prevention, lipid-lowering 
  treatment, fenofibric acid, statins
Introduction
Cardiovascular disease (CVD) constitutes the leading cause of death in developed coun-
tries. Current treatment guidelines focus on lowering low-density lipoprotein cholesterol 
(LDL-C) as the primary strategy for reducing CVD risk (Table 1).1–5 Hydroxymethyl-
glutamyl-coenzyme A reductase inhibitors (HMG-CoA) or statins have demonstrated a 
significant CVD risk reduction in a large number of landmark trials.6 There is growing 
evidence that both diabetic and nondiabetic patients are still at risk for CVD events 
even if they are receiving optimal statin treatment (termed as “residual CVD risk”). In 
the Pravastatin or Atorvastatin Evaluation and   Infection Therapy – Thrombolysis in 
Myocardial Infarction (PROVE IT-TIMI) 22 study, 4162 patients with acute coronary 
syndromes were treated with either pravastatin 40 mg or   atorvastatin 80 mg. A substan-
tial number of patients (10%) died from CVD events within 30 months, despite having 
LDL-C levels below 70 mg/dL (1.8 mmol/L).7 Similar were the   findings in the Treat-
ing to New Targets (TNT) study, where the level of residual CVD risk remained high 
in patients treated with atorvastatin 10 mg/dL or 80 mg/dL.8,9 This residual CVD risk 
seems to depend at least partly on increased levels of triglycerides (TG) and decreased 
levels of high-density lipoprotein cholesterol (HDL-C). Recent data indicate that up Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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to 50% of patients treated with a statin who have achieved 
LDL-C target levels have low HDL-C levels.10,11 In addition, 
based on current data, increased TG is nowadays considered 
to be a significant CVD risk factor.12
The  National  Cholesterol  Education  Program 
Adult Treatment Panel III (NCEP ATP III) recognized 
both low HDL-C (,40  mg/dL  [1.03  mmol/L]  for 
men, ,50 mg/dL [1.29 mmol/L] for women) and elevated 
TG levels ($150 mg/dL [1.69 mmol/L]) as markers of 
increased CVD risk, independently of LDL-C levels.1 
Mixed dyslipidemia, which is characterized by elevated 
TG ($50 mg/dL [1.69 mmol/L]) and low HDL-C   levels 
(,40 mg/dL [1.03 mmol/L] for men, ,50 mg/dL 
[1.29 mmol/L] for women) with or without increased LDL-
C, apolipoprotein (apo) B or non-HDL-C levels is typical 
in patients with type 2 diabetes and/or the metabolic syn-
drome.1,2,13 Mixed dyslipidemia is also characterized by an 
altered LDL subfraction profile with a preponderance of 
small dense LDL-C particles.14 Small dense LDL-C particles 
are considered to be highly atherogenic.2,15 Statins reduce 
LDL-C levels effectively, but they manifest limited effects 
on TG and HDL-C levels, as well as on LDL-C particle size 
modification, especially in patients with mixed dyslipidemia. 
There is accumulating evidence suggesting that treatment of 
patients with increased CVD risk, the metabolic syndrome, 
or diabetes should be oriented not only against decreas-
ing LDL-C, but also raising HDL-C levels.16,17 It becomes 
apparent that agents effective against these components of 
atherogenic dyslipidemia have an intriguing role to play in 
CVD risk reduction.18,19 However, there is no overwhelming 
evidence that treating these targets will alter major CVD 
outcomes. Furthermore, specific treatment goals for non-
LDL parameters are not currently defined.
Forty years since the introduction of the first fibrate in 
clinical practice, the exact role of these pharmacologic com-
pounds remains ill-defined.20 Fenofibrate is one of the most 
commonly prescribed lipid-lowering agents in the world. 
Trilipix® (fenofibric acid, ABT-335), is the newest formula-
tion of a fibric acid derivative approved by the Food and Drug 
Administration (FDA).21
Both statins and fibrates have favorable effects on several 
lipid and nonlipid parameters.22,23 Combining a statin with 
a fibrate may have a global beneficial effect because these 
two groups of pharmacologic agents differ in a substantial 
number of lipid and nonlipid parameters, and may in fact act 
in a complementary fashion.23,24 Updated guidelines from 
the NCEP ATP III recognize the potential beneficial effects 
of fibrates used in combination with a statin in patients with 
mixed dyslipidemia and coronary heart disease (CHD) or 
CHD risk equivalents.25
Aspects of pharmacology
Fenofibrate chemically is a 2-[4[(4-chlorobenzoyl)phenoxy]-
2-methyl-propanoic acid, 1-methylethyl ester. Hydrolysis of 
the ester bond converts fenofibrate to its active form, namely 
fenofibric acid.26 Fenofibrate is a lipophilic compound, and 
its absolute bioavailability is hard to estimate because it is 
highly insoluble in water. It is highly protein bound (99%), 
  primarily to albumin.26,27 Under normal conditions no 
unmodified fenofibrate is found in plasma.28 Plasma levels 
Table 1 Treatment targets for total cholesterol, LDL-C, and non-HDL-C, and cutoff values for triglycerides and HDL-C in the NCeP 
and eSC guidelines
Total cholesterol LDL-C non-HDL-Ca Triglyceridesb HDL-Cb
mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L mg/dL mmol/L
NCEP guidelines1,4 
General population 150 1.7 40 1.0
0 or 1 RF 160 4.1 190 4.9
More than 2 RF or 130 3.4 160 4.1
CAD event risk ,20%
CAD or risk equivalent1 100 2.6 130 3.4
Optional in very high risk 70 1.8 100 2.6
ESC guidelines5
General population 190 4.9 115 3.0 150 1.7 40 (M)  
45 (w)
1.0 (M)  
1.2 (w)
CAD, CVD or DM 175 4.5 100 2.6
Optional  155 4.0 80 2.1
Notes: ain the fasting state, non-HDL-C is calculated by subtracting HDL-C from total cholesterol and serves as a secondary target of therapy in patients with elevated 
triglycerides (.200 mg/dL, 2.26 mmol/L); bNo specific treatment goals are defined for HDL-C and fasting TG, but these concentrations serve as markers of increased CVD 
risk; cDefined as other clinical forms of atherosclerotic disease, diabetes mellitus, or a 10-year risk for CAD greater than 20%.
Abbreviations: CAD, coronary artery disease; CVD, cardiovascular disease; DM, diabetes mellitus; eSC, european Society of Cardiology; M, men; NCeP, National 
Cholesterol education Program; RF, risk factor; w, women. Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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peak in six to eight hours, while steady-state plasma levels 
are reached within 5 days. Its absorption is increased with 
meals, and the half-life is 16 hours.26,27,29
Fenofibric acid is inactivated by UDP-glucuronyltranferase 
into fenofibric acid glucuronide,30 and is mainly excreted in 
urine (60%) as fenofibric acid and fenofibric acid glucuronide 
(ester glucuronidation takes place in hepatic and renal 
tissues).26 As a result, fenofibric acid may accumulate in severe 
kidney disease (creatinine clearance, [CrCl] , 30 mL/min),28,31 
and is not eliminated by hemodialysis.31
Since the initial introduction of a fenofibrate in clinical 
practice, several other formulations have been developed in 
order to optimize its pharmacologic properties. The major 
drawbacks of the original fenofibrate formulation were 
its low availability and the necessitation of taking it with 
meals, especially fat meals. The new formulation is Trilipix 
(also known as fenofibric acid delayed-release or choline 
  fenofibrate) which is the choline salt of fenofibrate. Trilipix 
does not require enzymatic cleavage to become active. 
It rapidly dissociates to the active form of free fenofibric 
acid within the gastrointestinal tract and does not undergo 
first-pass hepatic metabolism.21
Trilipix is manufactured as delayed-release 45 mg 
and 135 mg capsules. The chemical name for choline 
  fenofibrate is ethanaminium, 2-hydroxy-N,N,N-trimethyl, 
2-{4-(4-  chlorobenzoyl)phenoxy] -2-methylpropanoate 
(1:1)32 (see Figure 1). It is freely soluble in water. Trilipix 
delayed-release capsules can be taken without regard to 
meals. Of great importance, fenofibric acid is well absorbed 
throughout the gastrointestinal tract, and has statistically 
greater   bioavailability than prior fenofibrate formulations, as 
has been demonstrated in healthy human volunteers.33
Pharmacokinetics
Fenofibric acid is the circulating pharmacologically active 
moiety in plasma after oral administration of Trilipix. Feno-
fibric acid is also the circulating pharmacologically active 
moiety in plasma after oral administration of fenofibrate, the 
ester of fenofibric acid. Plasma concentrations of fenofibric 
acid after one 135 mg delayed-release capsule are equivalent 
to those after one 200 mg capsule of micronized fenofibrate 
administered under fed conditions.
Absorption
Fenofibric acid is well absorbed throughout the   gastrointestinal 
tract. The absolute bioavailability of fenofibric acid is 
approximately 81%. The absolute bioavailability in the 
stomach, proximal small bowel, distal small bowel, and 
colon has been shown to be approximately 81%, 88%, 84%, 
and 78%, respectively, for fenofibric acid and 69%, 73%, 
66%, and 22%, respectively, for fenofibrate (P , 0.0001 
and P = 0.033 for fenofibric acid versus fenofibrate in the 
colon and distal small bowel, respectively).33 Fenofibric 
acid   exposure in plasma, as measured by time to peak 
  concentration in plasma and area under the concentration 
curve (AUC), is not significantly different when a single 
135 mg dose of Trilipix is administered under fasting or 
nonfasting conditions.34
Distribution
Upon multiple dosing of Trilipix, fenofibric acid levels reach 
steady state within 8 days.34 Plasma concentrations of fenofi-
bric acid at steady state are approximately slightly more than 
double those following a single dose.
Metabolism
Fenofibric acid is primarily conjugated with glucuronic acid 
and then excreted in urine. A small amount of fenofibric acid 
is reduced at the carbonyl moiety to a benzhydrol metabo-
lite which is, in turn, conjugated with glucuronic acid and 
excreted in urine.34 In vivo metabolism data after fenofibrate 
administration indicate that fenofibric acid does not undergo 
oxidative metabolism, eg, by cytochrome (CYP) P450, to a 
significant extent.
elimination
After absorption, Trilipix is primarily excreted in the urine in 
the form of fenofibric acid and fenofibric acid glucuronide. 
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Figure  1  Chemical  structure  of ABT-335. The  chemical  name  for  choline  fenofibrate  is  ethanaminium,  2-hydroxy-N,N,Ntrimethyl,  2-{4-(4-chlorobenzoyl)phenoxy]-2- 
methylpropanoate. The empirical formula is C22H28ClNO5 and the molecular weight is 421.91.Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Fenofibric acid is eliminated with a half-life of approximately 
20 hours,34 allowing once-daily administration of Trilipix.
Use in specific populations
In five elderly volunteers aged 77–87 years, the oral clearance 
of fenofibric acid following a single oral dose of fenofibrate 
was 1.2 L/hour, which compares with 1.1 L/hour in young 
adults. This indicates that an equivalent dose of fenofibric 
acid tablets can be used in elderly subjects with normal 
renal function, without increasing accumulation of the drug 
or metabolites. Trilipix has not been investigated in well-
controlled trials in pediatric patients. No pharmacokinetic 
difference between males and females has been observed 
for Trilipix. The influence of race on the pharmacokinetics 
of Trilipix has not been studied.
The pharmacokinetics of fenofibric acid were examined 
in patients with mild, moderate, and severe renal impairment. 
Patients with severe renal impairment (CrCl , 30 mL/min 
showed a 2.7-fold increase in exposure to fenofibric acid 
and increased accumulation of fenofibric acid during chronic 
dosing compared with healthy subjects.30 Patients with mild-
to-moderate renal impairment (CrCl 30–80 mL/min) had 
similar exposure but an increase in the half-life for fenofibric 
acid compared with that in healthy subjects. Based on these 
findings, the use of Trilipix should be avoided in patients who 
have severe renal impairment, and dose reduction is required 
in patients having mild to moderate renal impairment. No 
pharmacokinetic studies have been conducted in patients 
with hepatic impairment.
Drug–drug interactions
In vitro studies using human liver microsomes   indicate that 
fenofibric acid is not an inhibitor of CYP P450   isoforms 
CYP3A4, CYP2D6, CYP2E1, or CYP1A2. It is a weak 
  inhibitor of CYP2C8, CYP2C19, and CYP2A6, and a mild-to-
moderate inhibitor of CYP2C9 at therapeutic concentrations.34,35 
Accordingly, fenofibric acid may have the potential to cause 
various pharmacokinetic drug interactions.
Since they are highly protein-bound, all fibric acid 
derivatives may increase the anticoagulant effect of 
  coumarin derivatives. Serial monitoring of the International 
  Normalized Ratio should be performed. Caution should be 
exercised when drugs that are highly protein-bound are given 
concomitantly with fenofibrate.36
Interaction with cyclosporine has been reported to increase 
the risk of nephrotoxicity, myositis, and rhabdomyolysis, partly 
due to the fact that both are metabolized through CYP 3A4.37 
Careful consideration should be given when fenofibric acid 
is administered with other potential nephrotoxic drugs and, if 
necessary, lower doses of fenofibric acid may be used.21
Bile acid sequestrants may decrease the absorption of 
fenofibrate and therefore the bioavailability of fenofibric acid. 
It is recommended that fenofibrate be taken at least one hour 
before or 4–6 hours after bile acid resins.21
Concerning the pharmacokinetic interactions between 
  fenofibric acid and statins, no clinically significant 
  pharmacokinetic drug interaction between fenofibrate 
simvastatin, pravastatin, atorvastatin, and rosuvastatin has 
been observed in humans.38–41 Not all fibrates share the 
same   pharmacokinetic properties. In vitro studies have 
  demonstrated that   gemfibrozil interacts with the same family 
of glucuronidation enzymes involved in statin metabolism.35 
As a result of inhibiting statin glucuronidation, gemfibrozil 
coadministration with statins generally produces increases in 
the statin AUC. Gemfibrozil is also an inducer of CYP3A4, but 
acts as both an inducer and an inhibitor of CYP2C8.35 In con-
trast, fenofibrate is metabolized by different   glucuronidation 
enzymes and as a result, does not lead to pharmacokinetic 
interactions with statins in a clinically relevant way.35
Mode of action
effects on lipids
Fenofibric acid derivatives exert their primary effects 
on lipid metabolism via the activation of peroxisome 
  proliferator-activated receptor-alpha (PPAR-α) by the 
active fenofibric acid. Several target genes modulating lipid 
metabolism are encoded through the activation of these 
receptors.42,43 Fenofibrate affects the metabolism of TG and 
HDL-C through several pathways.
Fenofibrate is able to reduce plasma TG levels by inhibit-
ing their synthesis and stimulating their clearance. Primarily, 
fenofibrate induces fatty acid β-oxidation and, in this way, 
the availability of fatty acids for very LDL-C (VLDL-C) 
synthesis and secretion is reduced.44,45 Furthermore, it aug-
ments the activity of lipoprotein lipase (LPL) activity, which 
hydrolyzes TG on several lipoproteins.46
Apo C proteins are crucial for TG metabolism. Apo C III 
delays catabolism of TG-rich lipoproteins by inhibiting their 
binding to the endothelial surface and subsequent lipolysis 
by LPL. Fenofibrate decreases both apo C II and apo C III 
expression in the liver via PPAR-α activation.47–50 Apo C III 
reductions have also been shown to be the only significant and 
independent predictor of fenofibrate-induced TG alterations 
in obese patients with the metabolic syndrome.51
Apart from TG reduction, fenofibrate is well known for 
its favorable actions on HDL-C levels. The fundamental Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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action of fenofibrate is the promotion of apo A I and II 
synthesis in the liver, which represent the main HDL-C 
apoproteins.52 Fenofibrate modifies HDL and the reverse 
cholesterol transport pathway through several mechanisms. 
Specifically, fenofibrate is able to increase pre-β1-HDL-C 
levels in patients with the metabolic syndrome,53 reduce 
total plasma cholesteryl ester transfer protein activity,54,55 
induce the activity of adenosine triphosphate-binding 
cassette transporter (ABCA1,56,57 member 1 of the human 
transporter subfamily ABCA), also known as the cholesterol 
efflux regulatory protein (CERP), and induce hepatic lipase 
activity.46
Some recent clinical reports have suggested that HDL-C 
levels may be paradoxically decreased after fenofibrate 
treatment.58,59 This appears to occur mainly in patients with 
combined fibrate plus statin therapy and possibly in those 
with low baseline HDL-C. A survey of 581 patients treated 
with the combination for 1 year or longer indicated that 
paradoxical HDL-C reductions are a relatively uncommon 
phenomenon.59 Approximately 15% of patients showed mod-
est reduction in HDL-C levels. These reductions in HDL-C 
occurred mainly in individuals with significant HDL-C 
elevations (ie, .50 mg/dL, 1.3 mmol/L) and almost never 
in patients with low HDL-C. There was no impact of a pre-
vious diagnosis of diabetes or hypertension on the HDL-C 
changes.59
In addition, fibrates have been shown to decrease cho-
lesterol synthesis by inhibiting hydroxymethylglutamyl-
  coenzyme A reductase and to increase cholesterol excretion 
in the bile pool.55,60,61 Fenofibrate is able to reduce apo B 
levels, primarily as a result of reduced synthesis and secretion 
of TG, and not by directly influencing apo B production.45
effects on nonlipid parameters
Fenofibrate has beneficial effects on several nonlipid 
  parameters which are independent of its action on lipopro-
teins.62 As widely known, fibrates reduce   fibrinogen levels. 
  Fenofibric acid has been shown to inhibit   plasminogen acti-
vator inhibitor-1 and tissue factor expression on   endothelial 
cells and macrophages.63 Fenofibrate also   modulates platelet 
aggregation and endothelial dysfunction, via an incompletely 
elucidated molecular mechanism.64,65
Significant reductions in serum high sensitivity C-  reactive 
protein levels have been observed with   fenofibrate treat-
ment.63,66 Fenofibrate effectively decreases serum interleu-
kin-6 levels, as well as plasma platelet-activating factor 
acetylohydrolase, which represents a novel inflammatory 
marker.66,67
Of importance, fenofibrate can significantly decrease 
serum uric acid levels by increasing renal urate expression, 
and considerable reductions in serum alkaline phosphatase 
and gamma glutamyltransferase activity are commonly 
observed during therapy with fenofibrate.63,68 The latter 
effects may have an application in patients with liver diseases, 
including nonalcoholic fatty liver disease.
Recent reports have stressed the role of fenofibrate in 
glucose and carbohydrate metabolism. However, this issue 
remains controversial, with some studies demonstrating 
beneficial effects on insulin secretion51,66 and others   showing 
no effect.69
Studies evaluating the efficacy  
of fenofibrate
Fenofibrate as monotherapy
Fenofibrate is indicated for the treatment of   hypercholesterolemia, 
combined dyslipidemia, remnant hyperlipidemia, hypertrig-
lyceridemia, and mixed hyperlipidemia (  Frederickson types 
IIa, IIb, III, IV , and V , respectively).
Fenofibrate as monotherapy decreases serum TG levels by 
20%–50% and increases HDL-C levels by 10%–50%.48,70,71 
The rise in HDL-C levels depends on baseline HDL-C 
  concentrations, with the greatest elevations observed when 
baseline HDL-C is ,39 mg/dL (1.03 mmol/L).72 It also 
decreases LDL-C levels by 5%–20%.73 LDL-C response is 
directly related to baseline LDL-C levels and inversely related 
to baseline TG levels.73 In clinical practice, TG   reduction is 
greater in hypertriglyceridemia phenotypes (up to 50%) and 
lower in Type IIa hypercholesterolemia (,30%). Fenofibrate 
also exerts beneficial effects on several apolipoprotein levels. 
Apo A I and apo A II levels are significantly increased, while 
apo C III and apo B levels are reduced.48
Fenofibrate has been shown to modify favorably both 
LDL and HDL subclass distributions. Treatment with 
fenofibrate shifts the ratio of LDL-C particle subspecies 
from small, dense, atherogenic LDL particles (LDL 4 and 
LDL 5) to large, buoyant ones (LDL 3).54 These larger, 
less dense LDL particles show higher affinity for the LDL 
receptor, while an association between small dense LDL and 
increased CVD risk has long been established. In addition, 
fenofibrate is able to alter HDL particle size.54 The HDL-C 
rise is accompanied with a shift of HDL from large to small 
particles.48,53,54,74–76 The antiatherogenic, antioxidative, and 
antiapoptotic properties of HDL have been attributed mainly 
to its small subfractions.77,78 Furthermore, plasma levels of 
small HDL subclasses has been shown to be a strong   predictor 
of protection against atherosclerosis.79,80Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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Several large clinical and angiographic trials have 
  evaluated the efficacy of fibrates as monotherapy in halting 
the   progression of atherosclerotic disease (Table 2).81–85 The 
  Fenofibrate Intervention and Event Lowering in Diabetes 
(FIELD) study was a 5-year, randomized,   placebo-controlled 
trial testing the safety and efficacy of fenofibrate 200 mg 
in 9795 type 2 diabetic patients.86 The primary   endpoint 
was CHD death or nonfatal myocardial infarction (MI). 
  Fenofibrate failed to alter the primary endpoint   significantly. 
However,   fenofibrate reduced the composite of CVD death, 
MI, stroke, and coronary or carotid revascularization by 
11% (P = 0.035).   Interestingly, in this study, fenofibrate 
significantly reduced the need for retinal laser therapy (by 
30%, P , 0.001), the rate of nontraumatic amputation 
(by 38%, P = 0.011), and the   progression of albuminuria 
(P , 0.002). Of note, only 21% of the patients enrolled had 
Table 2 Major clinical and angiographic trials with fibrates
Study Patients Duration Fibrate Comparator Results
Helsinki heart study81 4081 male patients  
(40–55 years) with  
primary dyslipidemia  
and non-HDL-C  
levels . 200 mg/dL  
(5.17 mmol/L)
5 years Gemfibrozil  
1200 mg daily
Placebo 34% decrease in fatal 
and nonfatal Mi (95%  
Ci 8.2–52.6, P , 0.02)
Bezafibrate coronary  
atherosclerosis  
intervention study83
92 post-Mi  
patients , 45 years
5 years Bezafibrate 200 mg  
(3 times daily)
Placebo Less disease progression 
in focal lesions as 
assessed coronary 
angiograms in segments 
with ,50% diameter 
stenosis at baseline
LOPiD coronary  
angiography trial82
395 post-coronary  
bypass men # 70 years  
with HDL-C ,  
42.46 mg/dL  
(1.1 mmol/L) and  
LDL-C # 170 mg/dL  
(4.5 mmol/L)
32 months Gemfibrozil  
1200 mg daily
Placebo Decrease in rate 
of change in native 
coronary segments 
and minimum luminal 
diameter, and new 
lesions (2% for 
gemfibrozil vs 14% for 
placebo, P , 0.001)
Bezafibrate infarction  
prevention study85
3090 patients  
(45–74 years)  
with CHD
6.2 years Bezafibrate  
400 mg daily
Placebo Decrease by 9% in 
fatal and nonfatal Mi 
and sudden death 
(nonsignificant vs 
placebo)
Veterans affairs  
high-density  
lipoprotein  
cholesterol  
intervention study84
2531 patients  
(,74 years) with  
CHD and  
HDL-C , 39 mg/dL  
(1.03 mmol/L)
5.1 years Gemfibrozil  
1200 mg daily
Placebo Decrease by 24% in 
composite of CHD 
death, nonfatal Mi, 
stroke; by 24% in  
CVD events; by 25%  
in stroke, and by 22%  
in CHD death
Diabetes atherosclerosis 
intervention study88
418 patients aged  
40–65 years with  
DM and TC/HDL-C , 4  
or LDL-C , 170 mg/dL  
(4.5 mmol/L) or LDL-C 
135–170 mg/dL  
(3.5–4.5 mmol/L) and  
TG # 495 mg/dL  
(5.2 mmol/L)
3 years Fenofibrate  
200 mg daily
Placebo 40% decrease in 
minimum lumen 
diameter (P = 0.029  
vs placebo); 42% 
decrease in progression 
in percentage diameter 
stenosis (P = 0.02 vs 
placebo)
Fenofibrate  
intervention and  
event lowering in  
diabetes (FieLD)  
study86
9795 patients with  
type 2 diabetes,  
50–75 years,  
(2131 patients with 
documented CVD)
5 years Fenofibrate  
200 mg daily
Placebo 24% decrease in 
nonfatal Mi (P = 0.01  
vs placebo); 11% 
decrease in total CVD 
(P = 0.04 vs placebo)
Abbreviations: CHD, coronary heart disease; CVD, cardiovascular disease; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; TC, 
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mixed dyslipidemia (TG $ 200 mg/dL [2.25 mmol/L] and 
HDL-C , 40 mg/dL [1.03 mmol/L] for men and ,50 mg/dL 
[1.29 mmol/L] for women).   Fenofibrate decreased TG and 
LDL-C moderately (by 29% and 12%, respectively) and 
increased HDL-C by 5% at 4 months.86 Using the NCEP 
ATP III definition of metabolic syndrome, more than 80% 
of FIELD participants qualified as having the condition.87 
Each feature of metabolic syndrome,   excluding increased 
waist circumference, was associated with an increase in the 
absolute 5-year risk for CVD events by at least 3%. Marked 
dyslipidemia (defined as elevated   triglycerides $2.3 mmol/L 
and low HDL-C) was associated with the highest risk of 
CVD events (17.8%). The largest effect of fenofibrate on 
CVD risk reduction was observed in subjects with marked 
dyslipidemia, in whom a 27% relative risk reduction (95% 
confidence interval [CI] 9%–42%, P = 0.005; number needed 
to treat = 23) was observed.87
In the earlier Diabetes Atherosclerosis Interven-
tion Study (DAIS) study, 418 type 2 diabetic patients 
were enrolled (baseline lipid profile: LDL-C 132 mg/dL 
[3.4 mmol/L]; TG 221 mg/dL [2.49 mmol/L]; and HDL-C 
40 mg/dL [1.03 mmol/L]). DAIS was a 3-year, randomized, 
  placebo-controlled   angiographic trial.88   Fenofibrate slowed 
the   angiographic   progression of coronary   atherosclerosis, 
along with considerable improvement in the lipid profile 
(LDL-C reduction by 6%, TG reduction by 28%, and HDL-C 
increase by 7%). Fenofibrate decreased the   progression of 
focal   coronary atheroma by 40% versus placebo.   Additionally, 
fenofibrate decreased the incidence of microalbuminuria by 
54%.
Fibrate and statin combination therapy
It is well accepted that statins are the primary and more effi-
cient method of reducing LDL-C levels even at low doses.89 
However, statins manifest minimal effects in raising HDL-C 
levels (5%–15%) and in decreasing TG levels (7%–30%).19 
Fenofibrate has small or minimal effects on LDL-C levels, 
which depends on baseline TG levels.89 These data imply that 
a combination of a statin and a fibrate may have additional 
benefits, especially in patients with mixed dyslipidemia.
Combining fenofibrate with a statin appeared to be safe 
and effective in several short-term studies (Table 3).76,90–94 
The combination of fenofibrate with a statin, along with better 
improvements in lipid profile, has been shown to induce a 
marked increase in the ratio of large to small LDL subspecies 
compared with statin monotherapy.75,95
Long-term, placebo-controlled trials with the combina-
tion of a fibrate and a statin with hard CVD outcomes are 
lacking. In the Action to Control Cardiovascular Risk in 
Diabetes (ACCORD) Lipid study, researchers evaluated 
whether adding fenofibrate to statin therapy prevents adverse 
  cardiovascular events in patients with type 2 diabetes.96 A total 
of 5518 diabetic patients (mean age, 62 years; 31% women; 
glycosylated hemoglobin $ 7.5%; LDL-C 60–180 mg/dL 
[1.55–4.65 mmol/L]; HDL-C , 55 mg/dL [1.42 mmol/L] 
for women and blacks and ,50 mg/dL [1.29 mmol/L] for 
all other groups) were enrolled. All   participants received 
simvastatin 20–40 mg/day and also were assigned to daily 
fenofibrate 160 mg or   placebo. Mean follow-up was 4.7 years. 
Participants were also randomized to either intensive or 
standard glycemic control and to either intensive or standard 
blood pressure control. Glycemic control in the ACCORD 
study was stopped early in February 2008 because of 
higher mortality in the intensive glycemic control group. 
All patients were then transferred to a standard glycemic 
control regimen.
In both groups, mean LDL-C levels dropped from 
100.0  mg/dL  (2.59  mmol/L)  to  about  80.0  mg/dL 
(2.07 mmol/L). Mean HDL-C levels increased from 
38.0 mg/dL (0.98 mmol/L) to 41.2 mg/dL (1.07 mmol/L) in 
the fenofibrate group and to 40.5 mg/dL (1.05 mmol/L) in 
the placebo group. Median TG levels decreased from about 
189 mg/dL (2.13 mmol/L) to 147 mg/dL (1.66 mmol/L) 
in the fenofibrate group and to 170 mg/dL (1.92 mmol/L) in 
the placebo group.96 The primary endpoint, adverse (major 
fatal or nonfatal) cardiovascular events, occurred with 
similar frequency in the two groups (2.2% versus 2.4% per 
year; hazard ratio 0.92; P = 0.32).96 Among the secondary 
endpoints, there was also no statistically significant differ-
ence between the two treatments. No subgroup analysis 
was strongly positive. Only gender showed evidence of an 
interaction according to study group. The primary outcome 
for men was 11.2% in the fenofibrate group versus 13.3% 
in the placebo group, whereas the rate for women was 9.1% 
in the fenofibrate group versus 6.6% in the placebo group 
(P = 0.01 for interaction). A   possible benefit was also sug-
gested for patients who had a TG level in the highest third 
($204 mg/dL [$2.30 mmol/L]) and an HDL-C in the 
lowest third (#34 mg/dL [#0.88 mmol/L]). The primary out-
come rate was 12.4% in the fenofibrate group versus 17.3% 
in the placebo group, whereas such rates were 10.1% in both 
study groups for all other patients (P = 0.057 for interaction). 
Although patients receiving fenofibrate had higher rates of 
treatment discontinuation due to an increase in glomerular 
filtration rate (GFR), a lower incidence of both microalbu-
minuria (38.2% versus 41.6, P = 0.01) and macroalbuminuria Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
Dovepress 
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(10.5% versus 12.3%, P = 0.03) was noted in the fenofibrate 
group compared with the placebo group.96
Trilipix (ABT-335, fenofibric acid)  
clinical studies
The efficacy and safety of Trilipix has been evaluated in a large 
well-designed Phase III clinical program in   approximately 
2400 patients. Inclusion criteria consisted of elevated TG 
($150 mg/dL or 1.69 mmol/L), decreased HDL-C levels 
(,40 mg/dL or 1.03 mmol/L for men and ,50 mg/dL 
or 1.29 mmol/L for women), and elevated LDL-C levels 
($130 mg/dL or 3.36 mmol/L). Trilipix 135 mg was com-
pared as monotherapy and as combination therapy with three 
different statins (atorvastatin, rosuvastatin, and simvastatin). 
Primary efficacy endpoints were mean percentage changes 
in HDL-C and TG (comparing each combination with statin 
montherapy) and LDL-C levels (comparing each combination 
with Trilipix monotherapy).97 All three studies   consistently 
demonstrated that all Trilipix and statin dose groups resulted 
in greater increases in HDL-C and decreases in TG than the 
prespecified corresponding dose monotherapy. All three trials 
incorporated a 6-week dietary run-in period (during which 
patients underwent washout of any   lipid-lowering m  edication), 
a 12-week treatment period, and a 30-day follow-up period. In 
addition, at study end, patients could be enrolled in a 12-month 
open-label extension study in order to evaluate the long-term 
efficacy and safety of combination therapy.
In the first trial to be completed, 657 patients with mixed 
dyslipidemia were enrolled. Patients were randomized to 
Trilipix 135 mg or simvastatin 20, 40, or 80 mg, or to the 
combination of Trilipix 135 mg plus simvastatin 20 or 40 mg 
once daily for 12 weeks.98 The trial met its primary efficacy 
endpoints. The combination of Trilipix with   simvastatin 
20 mg or 40 mg was more potent in reducing TG and 
increasing HDL-C levels than monotherapy with simvas-
tatin 20 or 40 mg, and more potent in decreasing LDL-C 
levels   compared with Trilipix monotherapy. Specifically, 
the combination of Trilipix with simvastatin 20 mg raised 
HDL-C levels by 17.8%, while simvastatin 20 mg raised 
HDL-C by 7.2% (P , 0.001). The combination of Trilipix 
with simvastatin 20 mg resulted in a reduction in TG levels by 
37.4%, while monotherapy with simvastatin 20 mg lowered 
TG levels by 14.2% (P , 0.001). Trilipix with simvastatin 
reduced LDL-C levels by 24% while monotherapy with 
Trilipix reduced LDL-C levels by 4% (P , 0.001). The 
combination of Trilipix with simvastatin 40 mg resulted 
in improvement of all lipid parameters. Specifically, the 
  combination raised HDL-C levels by 18.9% compared with 
8.5% with simvastatin 40 mg monotherapy (P , 0.001), 
reduced TG levels by 42.7% versus 22.4% with simvastatin 
40 mg (P , 0.001), and reduced LDL-C levels by 25.3% 
(versus 4% with Trilipix monotherapy, P , 0.001).98
Regarding the secondary endpoints of the trial, both 
combinations (Trilipix with simvastatin 20 mg or 40 mg 
resulted in greater improvements in non-HDL-C levels and 
VLDL-C levels compared with simvastatin and Trilipix 
monotherapies. Trilipix with simvastatin 20 mg resulted in 
greater reductions in apo B protein levels compared with 
simvastatin 20 mg (P , 0.012).98
Trilipix was compared with atorvastatin in 613 patients 
with mixed dyslipidemia.99 Patients were randomly assigned 
to monotherapy with Trilipix 135 mg or atorvastatin 20, 40, 
or 80 mg, or the combination of Trilipix with atorvastatin 20 
or with 40 mg and treated for 12 weeks. Trilipix in combina-
tion with atorvastatin 20 mg resulted in a 45.6% reduction in 
TG levels versus 16.5% with atorvastatin 20 mg (P , 0.001). 
Regarding HDL-C levels, the combination increased HDL-C 
by 14%, while atorvastatin 20 mg increased HDL-C by 6.3% 
(P = 0.005). The combination also provided greater decreases 
in mean percentage LDL-C (33.7%) compared with Trilipix 
monotherapy (3.4%, P , 0.001). The results for the combina-
tion of Trilipix with atorvastatin 40 mg were similar, decreasing 
TG by 42.1% versus 23.2% with atorvastatin 40 mg mono-
therapy, while HDL-C increased by 12.6% versus 5.3% with 
atorvastatin 40 mg (P , 0.001 for TG and P = 0.01 for HDL-C). 
Trilipix with atorvastatin 40 mg decreased LDL-C levels by 
35.4% (P , 0.001 versus Trilipix monotherapy). Trilipix with 
atorvastatin 20 mg also resulted in higher decreases in non-
HDL-C levels compared with both monotherapies (P , 0.001 
versus Trilipix and P = 0.026 compared with atorvastatin 
20 mg). Apo B levels were significantly improved with com-
bination therapy of Trilipix and atorvastatin 20 mg compared 
with atorvastatin monotherapy (P = 0.046). Trilipix combined 
with atorvastatin 40 mg also resulted in greater improvements 
in non-HDL-C levels compared with Trilipix (P , 0.001), and 
higher decreases in VLDL-C compared with atorvastatin 40 mg 
(P , 0.001). Total cholesterol and high sensitivity C-reactive 
protein levels did not differ among groups.99
The third randomized trial included in the Trilipix evalu-
ation clinical program evaluated the efficacy and safety of 
Trilipix alone and in combination with rosuvastatin in a large 
number of patients with mixed dyslipidemia (n = 1445).100 
Patients were randomized to receive Trilipix 135 mg,   Trilipix 
plus rosuvastatin 10 or 20 mg, or rosuvastatin 10, 20, or 40 mg 
once daily for 12 weeks. Trilipix plus   rosuvastatin 10 mg 
increased HDL-C by 20.3% versus 8.5% with   rosuvastatin Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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10 mg alone (P , 0.001) and decreased TG by 47.1% versus 
24.4% (P , 0.001). The mean percentage reduction in LDL-C 
with the combination of Trilipix and rosuvastatin 10 mg was 
37.2%, compared with 6.5% with Trilipix monotherapy.
With the combination of Trilipix and rosuvastatin 20 mg, 
HDL-C decreased by 19% (mean percentage decrease) and by 
10.3% with rosuvastatin 20 mg monotherapy. TG levels were 
reduced by 42.9% with the combination and by 25.6% with 
rosuvastatin alone (P , 0.001). Trilipix plus rosuvastatin 
20 mg decreased LDL-C by 38.8% compared with Trilipix 
alone, which decreased LDL-C by 6.5% (P , 0.001).
Concerning the secondary efficacy endpoints, both 
combinations significantly improved non-HDL-C compared 
with Trilipix monotherapy. Trilipix plus rosuvastatin 10 mg 
resulted in greater improvements in VLDL-C, apo B, and 
high-sensitivity C-reactive protein than rosuvastatin 10 mg. 
Trilipix plus rosuvastatin 20 mg significantly improved 
VLDL-C levels and high-sensitivity C-reactive protein levels 
compared with rosuvastatin 20 mg.100
The long-term safety and efficacy of Trilipix combined 
with simvastatin, atorvastin, or rosuvastatin was examined 
in a Phase III, open-label, 2-year extension study in patients 
who had completed one of the three abovementioned double-
blind studies and the subsequent open-label, 1-year extension 
study. Of 310 patients enrolled, 287 completed the 2-year 
study.101 The primary efficacy endpoint was the percentage of 
subjects reporting adverse events during combination therapy 
in the preceding double-blind   studies or in the open-label 
1-year study or 2-year study. No deaths or treatment-related 
serious adverse events were reported. No case of rhab-
domyolysis occurred. The rate of   discontinuation was 2.9% 
overall. This study also   demonstrated that the improvements 
in HDL-C (+17.4%), TG (-46.4%), and LDL-C (-40.4%) 
were sustained.101
Additionally, a pooled subgroup analysis of the above-
mentioned, randomized, double-blind trials in 586 patients 
with mixed dyslipidemia and type 2 diabetes was per-
formed. It was demonstrated that fenofibric acid and statin 
  combination therapy in patients with mixed dyslipidemia 
and type 2 diabetes was well tolerated, and resulted in more 
comprehensive improvement in the lipid and apolipoprotein 
profile than either monotherapy.102
Safety and tolerability
Several trials show that fenofibrate is safe and well tolerated.73,86 
The most frequent adverse events are   gastrointestinal   symptoms 
(nausea and diarrhea) and musculoskeletal symptoms (myalgia 
and moderate elevation of creatine kinase). Other   uncommon 
adverse effects are skin reactions and   headache, fatigue, 
  vertigo, sleep disorders, and loss of libido.70,73
Fenofibrate may increase creatinine and urea levels by 12% 
and 8%, respectively, while some have reported increases up 
to 40% and 36%, respectively.103 In a double-blind, placebo-
controlled, 6-week trial, fenofibrate   treatment was shown to 
decrease GFR by less than 20% in subjects with normal renal 
function compared with placebo.104 Renal function   usually 
returns to baseline levels after drug discontinuation.103,105 
However, permanent increases in transplant recipients have 
been observed.103 It has been   suggested that fibrates may 
impair the generation of vasodilatory   prostaglandins via 
PPAR-α activation, which can   downregulate the   expression 
of the inducible COX-2 enzyme.106 In the FIELD substudy, 
changes in markers of renal function in 170 type 2 diabetic 
patients were addressed. It was confirmed than fenofibrate 
increased creatinine levels and concomitantly decreased 
GFR.107 However, no cases of renal failure have been 
described with fenofibrate monotherapy in the FIELD study. 
These changes complicate the clinical surveillance and jeop-
ardize compliance with fenofibrate treatment.
Indeed, in the ACCORD Lipid study, mean serum 
creatinine levels increased from 0.93 to 1.10 mg/dL (82 to 
97 µmol/L) in the fenofibrate group within the first year and 
remained relatively stable thereafter.96 The study drug was 
discontinued by 66 patients (2.4%) in the fenofibrate group 
and 30 (1.1%) in the placebo group because of a decrease 
in the estimated GFR. At the last clinic visit, 440 patients 
(15.9%) in the fenofibrate group and 194 (7.0%) in the 
  placebo group were receiving a reduced dose of either fibrate 
or placebo because of a decreased estimated GFR.96
The clinical relevance of the creatinine and GFR changes 
needs to be assessed in a long-term outcome study of renal 
function. Measurement of baseline creatinine values is advo-
cated. Routine monitoring of creatinine is not necessary. If a 
patient has a clinically important increase in creatinine, other 
potential causes of creatinine increase should be excluded, 
and consideration should be given to discontinuing fibrate 
therapy or reducing the dose.21
It is well known that fibrates (apart from gemfibrozil) 
can induce considerable increases in homocysteine levels.108 
Homocysteine levels have been speculated to increase CVD 
risk, however the clinical impact remains obscure.109,110 It 
has been suggested that the rise in homocysteine levels is 
directly related to the effects of fibrates on serum creatinine 
and on GFR, and mediated by PPAR-α activation. The rise 
in homocysteine levels has been implicated in the relative 
  ineffectiveness of fenofibrate in the FIELD study.86 It has Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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been suggested than increased homocysteine levels may 
reduce apo A I expression and may account for the small 
increases in HDL-c observed in the FIELD study.111
Fenofibrate is absolutely contraindicated in patients with 
severe renal or hepatic dysfunction, pre-existing gallbladder 
disease, or unexplained liver function abnormalities.
The greatest impediment in combining a fibrate with 
a statin is the potential risk of myopathy. Both fibrates 
and statins have been reported to cause myopathy and 
rhabdomyolysis.112–114 However, there are differences in 
myopathy risk between fibrates. Gemfibrozil in combina-
tion with any statin is   associated with a 15-fold higher risk 
of rhabdomyolysis than fenofibrate, because these two 
classes of drug are metabolized by the same glucuronidation 
enzymes, as mentioned above.115,116 In the FIELD study, no 
cases of rhabdomyolysis was described among 944 patients 
receiving fenofibrate plus a statin.86 In the ACCORD Lipid 
study, elevations of creatine kinase of more than 10 times 
the upper limit of the normal range at any time during the 
trial occurred in 10 patients (0.4%) in the fenofibrate group 
and 9 (0.3%) in the placebo group (P = 0.83).96 No cases of 
rhabdomyolysis were reported.96
Based on data from the FDA Adverse Event Reporting 
System fenofibrate may be the fibrate of choice for use in com-
bination with a statin, and fenofibric acid (Trilipix) is the only 
fibric acid derivative approved for use in combination with a 
statin. The safety of the newer formulation of fenofibric acid 
alone and in combination with low and moderate statin therapy 
was evaluated as part of the Phase III clinical programme. 
Fenofibric acid proved to be safe both as monotherapy and in 
combination with statins. In addition, the long-term safety of 
fenofibric acid combined with statins was tested for up to 2 
years in patients with mixed dyslipidemia. No deaths, rhab-
domyolysis, or other serious adverse events were reported. 
However, there are reports in the literature of coadministration 
of fenofibrate and statins inducing rhabdomyolysis.117–119 Cli-
nicians should be cautious, and other potential factors known 
to increase the risk of myopathy (eg, hypothyroidism, old age, 
and renal dysfunction) should be eliminated.119, 120
Treatment guidelines
According to several national guidelines, LDL-C reduction 
remains the primary target for treatment in both diabetic and 
nondiabetic for primary and secondary prevention.
In diabetic patients, although elevated LDL-C is not the 
major lipid abnormality, both the American Heart   Association 
(AHA) and the American Diabetes Association (ADA) 
  recognize lowering LDL-C as the primary   measure for CVD 
prevention. In type 2 diabetic patients, the   proposed target 
for LDL-C is ,100 mg/dL (2.59 mmol/L), while in 2008 the 
ADA proposed LDL-C to be ,70 mg/dL (1.81 mmol/L) in 
patients with diabetes and CVD.2
Several national guidelines have addressed the issue of 
high TG, non-HDL-C and low HDL-C, without reaching defi-
nite conclusions. NCEP ATP III proposes that when TG levels 
exceed 200 mg/dL (.2.25 mmol/L) non-HDL-C (LDL, 
VLDL-C, and intermediate-density lipoprotein) should be a 
secondary target of therapy after the LDL-C target has been 
achieved. Goals for non-HDL-C cholesterol are 30 mg/dL 
(0.77 mmol/L) higher than goals for LDL-C.
On the basis of Class C evidence, the ADA in 2008 proposed 
for diabetic patients a TG target , 150 mg/dL (1.69 mmol/L) 
and HDL-C . 40 mg/dL (1.03 mmol/L; for men) and above 
50 mg/dL (1.29 mmol/L; for women).121 While the AHA pro-
poses in diabetic patients that, if TG levels are above 200 mg/
dL (2.25 mmol/L), non-HDL-C should be below 130 mg/dL 
(3.36 mmol/L), without specifying a precise HDL-C target.2
Regarding secondary prevention, the AHA guide-
lines   propose that if TG levels are 200–499 mg/dL 
(2.25–5.6 mmol/L) non-HDL-C should be ,130 mg/dL 
(3.36 mmol/L) and even ,100 mg/dL (2.59 mmol/L) if 
patients are at very increased risk. This could be achieved 
either by lowering LDL-C levels more intensively or by add-
ing niacin or a fibrate.3
Updated guidelines from the NCEP ATP III recognize the 
potential of statin–fibrate combination therapy in patients with 
mixed dyslipidemia and CHD or CHD risk equivalents.25
All things considered, fenofibric acid is a useful adjunct 
indicated in combination with a statin to reduce TG and 
increase HDL-C in patients with mixed hyperlipidemia and 
CHD or CHD risk equivalents who are on optimal statin 
therapy to achieve the LDL-C goal. As monotherapy, it 
may be used to reduce TG levels in patients with severe 
  hypertriglyceridemia, to reduce total cholesterol, LDL-C, 
apo B, and TG, and to increase HDL-C in patients with 
primary hyperlipidemia or mixed hyperlipidemia. Trilipix 
  delayed-release capsules can be taken without regard to 
meals. For convenience, the daily dose of Trilipix may be 
taken at the same time as a statin, according to the dosing 
recommendations for each medication.
Conclusions
The existing burden of CVD will continue to increase as the 
population ages. Statins constitute the mainstay of treatment, 
both in primary and secondary CVD prevention. However, 
many patients remain at risk of CVD despite LDL-C being at Vascular Health and Risk Management 2010:6 submit your manuscript | www.dovepress.com
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the recommended targets. It is now widely understood that, 
apart from LDL-C, the pathophysiology of atherosclerosis 
incorporates a number of other risk factors, including athero-
genic dyslipidemia (elevated TG and low HDL-C levels) 
which should also be addressed.
Fenofibrate is a widely used hypolipidemic agent. Evi-
dence demonstrating significant CVD reduction with feno-
fibrate is not robust. In the FIELD study, fenofibrate failed 
to reduce the primary endpoint of CHD death or nonfatal 
MI.86 However, fenofibrate reduced significantly the com-
posite of CVD death, MI, stroke, and coronary or carotid 
revascularization. In addition, FIELD evaluated the effects 
of fenofibrate in a specific population (type 2 diabetics with 
a small percentage manifesting mixed dyslipidemia), and 
extrapolating these results in different populations is neither 
feasible nor reasonable. Although the results of FIELD may 
be relatively disappointing, the possibility of delaying both 
microvascular and macrovascular complications in diabetic 
patients is of particular importance. Hitherto, fenofibrate 
is the sole hypolipidemic treatment manifesting protection 
against microvascular events in diabetes patients.
The results of the ACCORD Lipid study were widely 
expected and not surprising, given that two-thirds of par-
ticipants would not be treated with fibrates under current 
guidelines.96 While the primary endpoint of the study was not 
met, in the prespecified subgroup of patients with atherogenic 
dyslipidemia (elevated TG and low HDL-C) fenofibrate plus 
simvastatin was associated with a 31% lower rate of fatal and 
nonfatal CVD events than simvastatin alone. In line with 
earlier clinical trials, fenofibrate also reduced micro- and 
macroalbuminuria,96 both of which are markers of diabetic 
renal disease.
Currently, national guidelines and expert authorities 
propose a fibrate to be used as an adjunctive measure when 
LDL-C or non-HDL-C targets have not been achieved with 
statins. Fenofibrate is the fibrate of choice for combination 
with a statin. Trilipix is a new fenofibric acid formulation 
approved for use as monotherapy and the only one to be 
approved for combination with statins. The efficacy and 
safety of Trilipix alone and in combination with rosuvas-
tatin, atorvastatin, or simvastatin have been extensively 
investigated in over 2400 patients with mixed dyslipidemia. 
Trilipix appears to be effective and safe both as monotherapy 
and in combination with statins. Trilipix may be taken with-
out regard to meals, and may have greater bioavailability 
compared with prior formulations. The ability of patients to 
maintain drug adherence over time, as well as to a healthy 
lifestyle, is of special importance both for quality of life and 
for CVD reduction, and this property may be proved to be 
considerably advantageous.122
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